InspireMD, developer of the novel MGuard(TM), a combination of a coronary stent merged with an embolic protection specifically designed for Acute MI (AMI) patients, received significant exposure at the ICI, Innovations in Interventional Cardiology, meeting this week in Tel-Aviv. InspireMD presented long-term data, including two years of clinical follow-up, to support the Company's MGuard stent technology.
The highlight of the meeting was InspireMD's sponsored symposium "MGuard, New Evidence in Acute MI," chaired by Dr. Martin B. Leon from Columbia University Medical Center, USA and co-chaired by Professor Chaim Lotan from Hadassah-Hebrew University Medical Center, Israel. Members of the panel were Dr. Dariusz Dudek from Poland, Prof. Jacob George from Israel and Dr. Sigmund Silber from Germany.
At the symposium, Dr. Dudek presented for the first time, a new Meta analysis of MGuard in AMI, illuminating the low adverse cardiac events (MACE) results and the excellent cardiac perfusion results of MGuard. Dr. Apro from Hungary and Dr. Galasso from Italy presented compelling data of MGuard in Acute MI, including two years clinical follow-up and six months angiographic follow-up. The distinguished panel embraced the results and discussed the advancement of MGuard into becoming an important tool in modern AMI therapy. In addition, challenging MGuard cases were presented by Dr. Cafri from Israel, Dr. La Manna from Italy, and Dr. Sztejfman from Argentina.
"For the first time, we presented long-term Meta analysis to support our MGuard technology, and we shared this data with a large audience of influential industry leaders," commented Asher Holzer, Ph.D, President of InspireMD. "This data confirmed and validated our initial data, reinforcing our belief that MGuard represents a powerful tool for embolic protection and AMI treatment."
Hourglass-shaped stent shows promise for treating microvascular disease